Description of the medicine: Distigmine bromide (Distigmine bromide)
DISTIGMINE BROMIDE (Distigmine bromide) *. 3-hydroxy-1-methylpyridinium hexamethylene bis- (N-methylcarbamate) dibromide.
Synonyms: Ubretid, Hexfmarium bromide, Ubretid, Ubretil.
White powder, soluble in water.
It is a long-acting cholinesterase inhibitor.
Applied for the prevention and treatment of postoperative intestinal atony, atony of the bladder, with an increase in the amount of residual urine in patients with neurogenic disorders of urination, myasthenia gravis and other indications for the use of anticholinesterase drugs (see Proserin, Oxazil) and cholipomimetics (see Aceclidine).
Assign inside and intramuscularly. Inside, give, starting with 0.5 mg (1 tablet) per day, then, depending on the effectiveness and tolerability of the drug, increase the dose to 2 tablets per day or reduce to 1 tablet 1 time in 2 to 3 days. Take in the morning on an empty stomach (1/2 hour before breakfast).
With myasthenia gravis, doses can be significantly increased, provided careful monitoring of tolerance and effectiveness is observed.
Intramuscularly administered 0.5 mg (1 ml of a 0.05% solution). Repeated injections are made no earlier than 24 hours after the first injection. If long-term treatment is necessary, 2 to 3-day breaks are recommended.
Possible side effects, precautions and contraindications are the same as for prozerin and other similar anticholinesterase drugs.
Method of release: tablets of 0.5 mg; 0.05% solution in ampoules of 1 ml (0.5 mg).